info@strategicmarketresearch.com
26, Broadway, Suite 934, New York , 10004
us US: +1-315-636-4233    uk UK: +44-162-237-0614     in IN: +91-826-083-6500
Home » Healthcare » Drug Delivery Devices Market Size, Analysis & Forecast 2030

Drug Delivery Devices Market By Route of Administration (Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal, Topical, Others), By Application (Oncology, Infectious Diseases, Respiratory Diseases, Diabetes, Cardiovascular Diseases, Autoimmune Diseases, Central Nervous System Disorders, Others), By End-User (Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics, Home Care Settings, Others), By Vehicles (Hydrogel, Micelle, Dendrimer, Nanoparticle, Liposome, Scaffold, Mesoporous Material, Niosomes), By Geography, Size, Share, Global Industry Report, Forecast, 2021-2030.

Published On: Jun-2022   |   Base Year: 2021   |   No Of Pages: 140   |   Historical Data: 2017 - 2020   |   Formats: PDF   |   Report ID: 40151841

Industry Report and Statistics (Facts & Figures) - Sales Volume & ASP by Route of Administration & Application

The global drug delivery devices market will witness a robust CAGR of 7.1%, valued at $239.2 billion in 2021, expected to appreciate and reach $340.45 billion by 2030, confirms Strategic Market Research. In terms of revenue, North America will account for the maximum industry share in 2020.

Providing medication or other pharmacological chemicals to accomplish a therapeutic effect is known as drug delivery. A drug delivery system is a device that provides a drug to the human body for absorption and administration. By managing the rate, time, and location of the ejection of a specific medicine throughout the body, drug delivery systems can offer a therapeutic dose of medication while also increasing safety and efficacy. Physical agents that make up the drug delivery system are known as drug delivery devices. This category encompasses a wide range of devices that people engage in and use daily. Novel drug delivery systems and combinations of products are being developed in modern pharmaceutical companies to meet versatile needs, which includes allowing patients to self-monitor some prescriptions at home, which can help them stick to prescribed regimens. According to the findings of the American Heart Association, cardiovascular disease (CVD) is responsible for roughly 800,000 fatalities in the United States. CVD is responsible for 31 % of all fatalities worldwide. By 2030, the cost of managing CVD is expected to be USD 1,044 billion. Nearly 48 % of women and 46 % of men in the African–American community have some kind of cardiovascular disease. The annual direct and indirect costs are expected to be USD 400 billion. Because of the high costs of pharmaceutical medicines and the need to reduce healthcare spending, novel drug delivery systems can assist in more efficient and accurate drug use. Autoinjectors, Prefilled syringes, metered dose inhalers (MDIs), nasal sprays, nebulizers, transdermal patches, intrauterine devices (iuds), eyedroppers, Infusion pumps, microneedle arrays are some of the drug delivery devices available in the market. These devices are used for medical treatments one or more times. The rising prevalence of acute and chronic illnesses increased R&D spending, and improved government support are the primary drivers of the market.

Drug Delivery Devices Market Infographics

Key Industry Drivers - The Rising Incidence of Acute and Chronic Illnesses Increased R&D Spending and Improved Government Support.

  • The rising frequency of acute and chronic illnesses and infections worldwide is one of the primary reasons driving the overall drug delivery devices market value. As per recent research, there are more than 20 million diabetics, which will grow to 57 million by 2025. According to CDC, T.B. germs affected 1.7 billion people, or nearly 23% of the world's population. TB is the world's greatest infectious disease, killing 1.5 million people annually.

 

  • A rise in R&D spending on medical instruments and devices, particularly in established and emerging nations, will generate even more profitable industry growth prospects. According to one McKinsey survey, the European Union would invest around EUR 7 billion in health research between 2021 and 2027 as part of the Horizon Europe initiative. Moreover, in the Fiscal Year 2020, the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) delivered HIV testing to almost 50 million individuals and funded lifesaving ART for approximately 18.2 million men, women, and children. The growth rate is also being boosted by research and development capabilities (use of polymers in drug delivery) over live viruses to develop medications.

 

  • Moreover, the federal government's increased spending is expected to fuel the pace of market growth. According to the Centers for Medicare & Medicaid Services findings, healthcare spending by the federal government increased to 36.0 % in 2020, compared to 5.9 % in 2019. The COVID-19 pandemic was a major factor in this faster growth. In 2020, hospital spending increased by 6.4 % to $1,270.1 billion, faster than the 6.3 % increase in 2019. Furthermore, the healthcare business's expansion and rise, driven by public and private players (e.g., vaccine delivery), will generate lucrative growth prospects, particularly in developing nations.

Total market share of drug delivery devices from 2020-2030

Restraints - Lack of Standardization, Less Number of Professionals, and High Product Cost

  • Lack of standardization, strict approval of drugs, risk of nanoparticles entering the brain, lack of knowledgeable professionals to use some of the devices, and higher cost of technologically advanced devices are restraining the drug delivery devices market growth. 

 

Opportunities - Focus on Preventative Treatment, Improved R&D, and Rise in Disposable Income

  • Increases in personal disposable income, the initiation of technologically driven products in hospitals, increased investment in the development of advanced medical products such as nano-based drug delivery systems, transdermal drug delivery, intracellular delivery (for drug), niosomes, liposomes, microencapsulation, and a rise in the number of cancer cases, respiratory diseases, and diabetic patients in underdeveloped economies all have a positive impact on the growth rate of the industry. The National Council on Aging reported that around 85 % of adults suffer at least one chronic condition. Chronic illnesses are the biggest cause of the nation's healthcare expenses, totaling $3.8 trillion annually. Chronic pain and diabetes are the most expensive chronic illnesses, costing $635 billion and $327 billion annually.

 

  • Increased public-private financing for targeted research efforts, growing air pollution levels, and increased new products and development due to technological breakthroughs worldwide will provide profitable prospects for market participants over the projection period. B.D. (Becton, Dickinson, and Company) has announced plans to establish a €165 million (USD 200 million) high-tech production facility in Zaragoza, Spain, to generate up to 600 jobs by 2030. Zaragoza is located in the Aragon area of Spain. As part of B.D.'s 2025 expansion strategy, the new facility represents a piece of the USD 1.2 billion investment announced in December 2020 to expand and modernize production capabilities and technologies for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS).

End-user included in the drug delivery devices market

Drug Delivery Devices Market Analysis Of Different Segments Covered in the Report

The industry segmentation analysis is based on the Route of Administration, Application, End Users, and Region.

Based on Route of Administration

  • Ocular

  • Oral

  • Inhalation

  • Topical

  • Injectable

  • Nasal

  • Others

 

Based on Application

  • Cancer

  • Diabetes

  • Cardiovascular

  • Infectious Diseases

  • Others

 

Based on End-user

  • Ambulatory Services

  • Hospitals

  • Home Healthcare

 

Vehicles Outlook (Volume, Units; Revenue, USD Billion, 2016 - 2027)

  • Hydrogel

  • Micelle

  • Dendrimer

  • Nanoparticle

  • Liposome

  • Scaffold

  • Mesoporous Materia

  • Niosomes

 

Regional Coverage Analysis

North America

  • The U.S.

  • Canada

  • Europe

  • The U.K.

  • Germany

  • France

 

Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Rest of the World

 

Route of Administration Analysis & Insights

Based on Route of Administration, the oral category held the biggest market share in 2020 due to the rising popularity of oral medication administration, which is painless, easy for patients, cost-effective, non-invasive, and self-administered. Atorvastatin, the most widely recommended medicine, was prescribed to 24.5 million people in the United States, or 7.5 % of the population. It was one of many statin drugs listed, used to treat abnormal lipid levels and prevent cardiovascular disease. Patients on blood pressure or cholesterol medicine account for 33 % of the population in the United States. Furthermore, most pharmaceuticals or medicines are accessible in liquid, powder, and tablet forms and are often delivered orally. The topical is expected to become the most promising market during the foreseeable term, and the nasal drug delivery devices market is forecasted to grow with a CAGR of 6.5%. 

 

Application Analysis & Insights

Based on Application, in 2020, the cancer sector held the greatest market share due to the growing number of cancer cases among the common population. Cancer cases globally are expected to increase by 47% between 2020 and 2040. Globally, 28.4 million instances are predicted to be documented by 2040. The National Cancer Institute reported that there would be 1,918,030 new cancer cases and 609,360 cancer deaths in the United States in 2022, with lung cancer being the leading cause of cancer mortality, accounting for nearly 350 fatalities each day. As a result, the rising incidence of breast, lung, bowel, and womb cancer are the primary drivers of this category. CVDs in total accounted for 32% of worldwide fatalities in 2019, as per the World Health Organization. As a result, the cardiovascular category is expected to grow fastest over the projection period.

 

End Users Analysis & Insights

Based on End Users, in 2020, the hospital category will have the highest revenue share based on end-user, attributable to growing hospital penetration worldwide. Rising government and business sector investments in hospital expansion have contributed to the rise of this market. The health ministry of the United Kingdom confirmed that 40 hospitals would be built by 2030 as part of a £3.7 billion program. By 2029, the Singapore government's healthcare spending will reach $36 billion, while private healthcare spending will reach $13.5 billion. On the other side, the home healthcare category is expected to be one of the most promising markets throughout the projected period.

 

Region Analysis & Insights

Based on Region, in terms of revenue, North America will account for the lion's share in 2020, and this is due to the increased prevalence of chronic illnesses such as cancer, diabetes, and CVDs in the United States. According to the American Cancer Society, brain malignancy will be the second most often detected cancer in children and adolescents, with 27 % and 21 % in 2021. In addition, according to the American Cancer Society, USD 23.1 million has been set aside for brain-related clinical and cancer control research in the United States as of August 2020. Furthermore, growing health consciousness and healthcare expenditure in the United States have fuelled the market expansion. The Asia Pacific is on the verge of becoming the most promising market during the projection period. Furthermore, the rapidly expanding senior population will likely increase market demand since the elderly are more susceptible and prone to illnesses. As per the United Nations, poor and middle-income nations will house 80 % of the world's senior population.

 

Drug Delivery Devices Market Report Coverage

Report Attribute

Details

Forecast Period

2021 - 2030

The market size value in 2021

USD 239.2 billion

The revenue forecast in 2030

USD 340.45 billion

Growth rate

CAGR of 4.0 %

The base year for estimation

2021

Historical data

2017 – 2020

Unit

USD Billion, CAGR (2021 - 2030)

Segmentation

By Route of Administration, By Application, By End User, By Region

In terms of Route of Administration

Ocular, Oral, Inhalation, Nasal, Injectable, Topical, Others

In Terms of Application

Diabetes, Cancer, Infectious Diseases, Cardiovascular, Others

By End-User

Ambulatory Services, Home Healthcare, Hospitals.

By Region

North America, Asia Pacific, Europe, and The Rest of the world

Country Scope

Canada, Mexico, US, Germany, UK, France, India, Japan, China etc.

Company Usability Profiles

Pfizer, Inc, Novartis AG, Bayer AG, Shenzhen (SiBiono) , GeneTech Company Ltd.(Hubei Tongji Benda Ebei Pharma), F. Hoffmann-La Roche, 3M, Johnson & Johnson Services, Antares Pharma, Inc, uniQure N.V,

 

Global Drug Delivery Devices Market Competitive Landscape Analysis

The existing competitive market analysis gives an overview of some of the key players operating in the global market. Product innovation, Increased investments by venture capitalists, and continued R&D operations to create advanced, sophisticated technologies have assisted the market's growth. In the target market, there are many flourishing companies, and some of the industry leaders are:

 

Regional coverage of the drug delivery devices market

Industry Recent Developments:

  • On April 2022, Covestro unveiled a proof-of-concept medication delivery system with its range of medical-grade polycarbonate resins. The gadget employs distinct polycarbonates in every piece, simplifying sorting and recycling when discarded bio-contaminated portions.

 

  • On December 2021, researchers at Monash University's Australian Centre for Blood Diseases invented the globe's first metal-organic framework antibody-drug delivery system, which has the capability to accelerate the development of new cancer, cardiovascular, and autoimmune therapies. When MOF antibody crystals connect to their target cancer cells and are subject to the cells' low pH, they break down, delivering the medications directly and solely to the appropriate location, according to the in vitro study.

 

  • On January 2021, Credence MedSystems, a drug delivery startup, announced that Novartis had made a strategic investment in the company. The investment will support Credence's continuous research and expansion of new medication delivery systems, with an initial emphasis on the Credence Companion Safety Syringe System.

 

  • On May 2020, Kindeva, a worldwide contract manufacturing/development corporation specializing in medication delivery projects, relaunched 3M's drug delivery systems, and this is the newly created independent firm founded in conjunction with Altair following the USD 650 million sales of drug delivery system units to Altair Capital Partners.

 

Various Types of Equipment that the Global Market Leaders are Manufacturing:

Name

Feature

Key Player

hMTS

Easy self-administration of the drug.

3M

 

Unidose Powder System

A single-use, ready-to-use one-step nasal administration device is designed to deliver a powder formulation quickly and conveniently in an emergency.

Aptar CSP Technologies

 

SYNCHROMED II INTRATHECAL PUMP

An implanted catheter administers medicine to the intrathecal area using the SynchroMed II programmable, implantable pump. The Control WorkflowSM technique, which is created to minimize systemic opioids and offer effective pain treatment, can be used to manage SynchroMed II pumps.

Medtronic

 

 

Frequently Asked Question About This Report

Rising incidence of acute and chronic illnesses, increased R&D spending, and improved government support are the primary drivers of the market.

It is predicted to reach USD 340.45 billion by 2030, with a CAGR of 4 % throughout the forecasted period.

The CAGR of the drug delivery devices market is 4 %.

In terms of revenue, North America will account for the lions share in 2021

Some major players are Johnson & Johnson Services, Bayer AG, F. Hoffmann-La Roche, 3M, uniQure N.V, Novartis AG, Pfizer, Inc.

In 2021, the Global Drug Delivery Devices Market share was USD 239.2 billion and is estimated to reach $340.45 Billion by 2030, representing a CAGR of 7.1%

Sources

https://professional.heart.org/en/science-news/heart-disease-and-stroke-statistics-2022-update

https://www.cdc.gov/tb/worldtbday/history.htm

https://www.mckinsey.com/capabilities/strategy-and-corporate-finance/our-insights/securing-europes-competitiveness-addressing-its-technology-gap

https://www.cms.gov/newsroom/press-releases/national-health-spending-2020-increases-due-impact-covid-19-pandemic

https://www.cancer.org/research/cancer-facts-statistics/global.html

 

 

1.   Introduction

       1.1. Study Objective

       1.2. Market Definition        

       1.3. Study Scope

              1.3.1. Markets Covered

              1.3.2. Geographic Scope

              1.3.3. Years Considered

              1.3.4. Stakeholders

2.   Research Methodology

       2.1. Data Procurement

       2.2. Paid Database

              2.2.1. Secondary Data

                     2.2.1.1. Key Secondary sources

              2.2.2. Primary Data

                     2.2.2.1 Primary sources

                     2.2.2.2. Key industry insights

                     2.2.2.3. Primary interviews with experts

                     2.2.2.4. Key primary respondent list

       2.3. Market Size Estimation

       2.4. Bottom-Up and Top-Down Approaches

              2.4.1.     Bottom-Up Approach

                     2.4.1.1.         Approach for arriving at market size by bottom-up analysis

              2.4.2.     Top-Down Approach

                     2.4.2.1.         Approach for Capturing Market Size by Top-Down Analysis

       2.5. Market Breakdown and Data Triangulation

       2.6. Research Methodology

       2.7. Risk Assessment

3.  Executive Summary

       3.1 Drug Delivery Devices Market: Post-Covid-19

              3.1.1      Actual Scenario

              3.1.2      Pessimistic Scenario

              3.1.3      Optimistic Scenario

              3.1.4      Market Summary

4. Industry Outlook

       4.1 Market Snapshot

       4.2 Drug Delivery Devices Market

              4.2.1      market, 2021 – 2030 (USD Million)

       4.3 Regional Business Analysis

              4.3.1      market, by region, 2021 - 2030 (USD Million)

       4.4 By Route of Administration Business Analysis

              4.4.1      market, By Route of Administration, 2021 - 2030 (USD Million)

       4.5 By Application Business Analysis

              4.5.1      market, By Application, 2021 - 2030 (USD Million)

       4.6 Vehicles Business Analysis

              4.6.1      market, By Vehicles, 2021 - 2030 (USD Million)

       4.6 End-user Business Analysis

              4.6.1      market, By End-user, 2021 - 2030 (USD Million)

       4.7 Value Chain Analysis

       4.8 Market Variable Analysis

              4.8.1      Market Drivers Analysis

              4.8.2      Market Restraints Analysis

       4.9 Business Environment Analysis Tool

              4.9.1      market PEST analysis

              4.9.2      market Porter’s analysis

       4.10 Penetration & Growth Prospect Mapping

5. Market Dynamics

       5.1. Introduction

       5.2. Market Dynamics

              5.2.1.     Drivers

              5.2.2.     Restraints

              5.2.3.     Opportunities

              5.2.4.     Challenges

       5.3. Impact of Covid-19 On Market

       5.4. Value Chain Analysis

       5.5. Ecosystem

       5.6. Patent Analysis

       5.7. Trade Analysis

       5.8. Tariff Analysis

       5.9. Case Study Analysis

5.10.      Porter’s Five Forces Analysis

              5.10.1    Threat of New Entrants

              5.10.2    Threat of Substitutes

              5.10.3    Bargaining Power of Buyers

              5.10.4    Bargaining Power of Suppliers

              5.10.5    Degree of Competition

       5.11.              End-user Analysis

              5.11.1.   Trends in End-user (2014-2021)

              5.11.2.   Trends in End-user (2021-2030)

       5.12.              Pricing Analysis

              5.12.1.   Average Price Trend Analysis (By Region, By Country)

6. Competitive & Vendor Landscape

       6.1. Company Market Share Analysis

       6.2. Manufacturers Manufacturing Sites, Area Served, Route of Administration

       6.3. Market Competitive Situation and Trends

       6.4. Manufacturers Mergers & Acquisitions, Expansion Plans

7. Market: By Route of Administration Segment Analysis

       7.1. Introduction

       7.2. Sales Volume & Revenue Analysis (2021-2030)

       7.3. Oral

              7.3.1. Oral market, 2021 - 2030 (USD Million)

       7.4. Inhalation

               7.4.1. Inhalation market, 2021 - 2030 (USD Million)

       7.5. Transdermal

               7.5.1. Transdermal market, 2021 - 2030 (USD Million)

       7.6. Injectable

               7.6.1. Injectable market, 2021 - 2030 (USD Million)

       7.7. Ocular

               7.7.1. Ocular market, 2021 - 2030 (USD Million)

       7.8. Nasal

               7.8.1. Nasal market, 2021 - 2030 (USD Million)

       7.9. Topical

               7.9.1. Topical market, 2021 - 2030 (USD Million)

       7.10. Others

               7.10.1. Others market, 2021 - 2030 (USD Million)

8. Market: By Application Segment Analysis

       8.1. Introduction

       8.2. Sales Volume & Revenue Analysis (2021-2030)

       8.3. Oncology

              8.3.1.     Oncology market, 2021 - 2030 (USD Million)

       8.4. Infectious Diseases

              8.4.1.     Infectious Diseases market, 2021 - 2030 (USD Million)

       8.5. Respiratory Diseases

              8.5.1.     Respiratory Diseases market, 2021 - 2030 (USD Million)

       8.6. Diabetes

              8.6.1.     Diabetes market, 2021 - 2030 (USD Million)

       8.7. Cardiovascular Diseases

              8.7.1.     Cardiovascular Diseases market, 2021 - 2030 (USD Million)

       8.8. Autoimmune Diseases

              8.8.1.     Autoimmune Diseases market, 2021 - 2030 (USD Million)

       8.9. Central Nervous System Disorders

              8.9.1.     Central Nervous System Disorders market, 2021 - 2030 (USD Million)

       8.10. Others

              8.10.1.     Others market, 2021 - 2030 (USD Million)

9. Market: By Vehicles Segment Analysis

       9.1. Introduction

       9.2. Sales Volume & Revenue Analysis (2021-2030)

       9.3. Hydrogel

              9.3.1.     Hydrogel market, 2021 - 2030 (USD Million)

       9.4. Micelle

              9.4.1.     Micelle market, 2021 - 2030 (USD Million)

       9.5. Dendrimer

              9.5.1.     Dendrimer market, 2021 - 2030 (USD Million)

       9.6. Nanoparticle

              9.6.1.     Nanoparticle market, 2021 - 2030 (USD Million)

       9.7. Liposome

              9.7.1.     Liposome market, 2021 - 2030 (USD Million)

       9.8. Scaffold

             9.8.1.     Scaffold market, 2021 - 2030 (USD Million)

       9.9. Mesoporous Material

              9.9.1.     Mesoporous Material market, 2021 - 2030 (USD Million)

       9.10. Niosomes

              9.10.1.     Niosomes market, 2021 - 2030 (USD Million)

10. Market: By End-user Segment Analysis

       10.1. Introduction

       10.2. Sales Volume & Revenue Analysis (2021-2030)

       10.3. Hospitals

              10.3.1.   Hospitals market, 2021 - 2030 (USD Million)

       10.4. Diagnostic Centers

              10.4.1.   Diagnostic Centers market, 2021 - 2030 (USD Million)

       10.5. Ambulatory Surgery Centers/Clinics

              10.5.1.   Ambulatory Surgery Centers/Clinics market, 2021 - 2030 (USD Million)

       10.6. Home Care Settings

              10.6.1.   Home Care Settings market, 2021 - 2030 (USD Million)

       10.7. Others

              10.7.1.   Others market, 2021 - 2030 (USD Million)

11. Market: Regional Outlook

       11.1 North America

              11.1.1.   North America market, By Route of Administration, 2021 - 2030 (USD Million)

              11.1.2.   North America market, By Application, 2021 - 2030 (USD Million)

              11.1.3.   North America market, by End-user, 2021 - 2030 (USD Million)

              11.1.4.   North America market, by Country, 2021 - 2030 (USD Million)

       11.1.4.1. U.S.

                     11.1.4.1.1.   U.S. market, By Route of Administration, 2021 - 2030 (USD Million)

                     11.1.4.1.2.   U.S. market, By Application, 2021 - 2030 (USD Million)

                     11.1.4.1.3.   U.S. market, by End-user, 2021 - 2030 (USD Million)

     11.1.4.2.  Canada

                     11.1.4.2.1.   Canada market, By Route of Administration, 2021 - 2030 (USD Million)

                     11.1.4.2.2.   Canada market, By Application, 2021 - 2030 (USD Million)

                     11.1.4.2.3.   Canada market, by End-user, 2021 - 2030 (USD Million)

11.2. Europe

              11.2.1.   Europe market, By Route of Administration, 2021 - 2030 (USD Million)

              11.2.2.   Europe market, By Application, 2021 - 2030 (USD Million)

              11.2.3.   Europe market, by End-user, 2021 - 2030 (USD Million)

              11.2.4.   Europe market, by country, 2021 - 2030 (USD Million)

    11.2.4.1    U.K.

                     11.2.4.1.1.   U.K. market, By Route of Administration, 2021 - 2030 (USD Million)

                     11.2.4.1.2.   U.K. market, By Application, 2021 - 2030 (USD Million)

                     11.2.4.1.3.   U.K. market, by End-user, 2021 - 2030 (USD Million)

   11.2.4.2.           Germany

                     11.2.4.2.1.   Germany market, By Route of Administration, 2021 - 2030 (USD Million)

                     11.2.4.2.2.   Germany market, By Application, 2021 - 2030 (USD Million)

                     11.2.4.2.3.   Germany market, by End-user, 2021 - 2030 (USD Million)

   11.2.4.3.           France

                     11.2.4.3.1.   France market, By Route of Administration, 2021 - 2030 (USD Million)

                     11.2.4.3.2.   France market, By Application, 2021 - 2030 (USD Million)

                     11.2.4.3.3.   France market, by End-user, 2021 - 2030 (USD Million)

    11.2.4.4.          Rest of Europe

                     11.2.4.4.1.   Rest of Europe market, By Route of Administration, 2021 - 2030 (USD Million)

                     11.2.4.4.2.   Rest of Europe market, By Application, 2021 - 2030 (USD Million)

                     11.2.4.4.3.   Rest of Europe market, by End-user, 2021 - 2030 (USD Million)

       11.3.              Asia Pacific

              11.3.1.   Asia Pacific market, By Route of Administration, 2021 - 2030 (USD Million)

              11.3.2.   Asia Pacific market, By Application, 2021 - 2030 (USD Million)

              11.3.3.   Asia Pacific market, by End-user, 2021 - 2030 (USD Million)

              11.3.4.   Asia Pacific market, by country, 2021 - 2030 (USD Million)

   11.3.4.1.           China

                     11.3.4.1.1.   China market, By Route of Administration, 2021 - 2030 (USD Million)

                     11.3.4.1.2.   China market, By Application, 2021 - 2030 (USD Million)

                     11.3.4.1.3.   China market, by End-user, 2021 - 2030 (USD Million)

   11.3.4.2.           India

                     11.3.4.2.1.   India market, By Route of Administration, 2021 - 2030 (USD Million)

                     11.3.4.2.2.   India market, By Application, 2021 - 2030 (USD Million)

                     11.3.4.2.3.   India  market, by End-user, 2021 - 2030 (USD Million)

   11.3.4.3.           Japan

                     11.3.4.3.1.   Japan market, By Route of Administration, 2021 - 2030 (USD Million)

                     11.3.4.3.2.   Japan market, By Application, 2021 - 2030 (USD Million)

                     11.3.4.3.3.   Japan market, by End-user, 2021 - 2030 (USD Million)

   11.3.4.4.           South Korea

                     11.3.4.4.1.   South Korea market, By Route of Administration, 2021 - 2030 (USD Million)

                     11.3.4.4.2.   South Korea market, By Application, 2021 - 2030 (USD Million)

                     11.3.4.4.3.   South Korea market, by End-user, 2021 - 2030 (USD Million)

11.3.4.5.              Rest of ASIA PACIFIC

                     11.3.4.5.1.   Rest of ASIA PACIFIC market, By Route of Administration, 2021 - 2030 (USD Million)

                     11.3.4.5.2.   Rest of ASIA PACIFIC market, By Application, 2021 - 2030 (USD Million)

                     11.3.4.5.3.   Rest of ASIA PACIFIC market, by End-user, 2021 - 2030 (USD Million)

       11.4.              Latin America

              11.4.1.   Latin America market, By Route of Administration, 2021 - 2030 (USD Million)

              11.4.2.   Latin America market, By Application, 2021 - 2030 (USD Million)

              11.4.3.   Latin America market, by End-user, 2021 - 2030 (USD Million)

              11.4.4.   Latin America market, by country, 2021 - 2030 (USD Million)

11.4.4.1.              Brazil

                     11.4.4.1.1.   Brazil market, By Route of Administration, 2021 - 2030 (USD Million)

                     11.4.4.1.2.   Brazil market, By Application, 2021 - 2030 (USD Million)

                     11.4.4.1.3.   Brazil market, by End-user, 2021 - 2030 (USD Million)

11.4.4.2.              Mexico

                     11.4.4.2.1.   Mexico market, By Route of Administration, 2021 - 2030 (USD Million)

                     11.4.4.2.2.   Mexico market, By Application, 2021 - 2030 (USD Million)

                     11.4.4.2.3.   Mexico market, by End-user, 2021 - 2030 (USD Million)

                     11.4.4.3.       Rest of the Latin America

                     11.4.4.3.1.   Rest of the Latin America market, By Route of Administration, 2021 - 2030 (USD Million)

                     11.4.4.3.2.   Rest of the Latin America market, By Application, 2021 - 2030 (USD Million)

                     11.4.4.3.3.   Rest of the Latin America market, by End-user, 2021 - 2030 (USD Million)

       11.5.              MEA

              11.5.1.   MEA market, By Route of Administration, 2021 - 2030 (USD Million)

              11.5.2.   MEA market, By Application, 2021 - 2030 (USD Million)

              11.5.3.   MEA market, by End-user, 2021 - 2030 (USD Million)

              11.5.4.   MEA market, by Region, 2021 - 2030 (USD Million)

 

12. Competitive Landscape

       12.1 Bayer AG

              12.1.1.   Company overview

              12.1.2.   Financial performance

              12.1.3.   Route of Administration Portfolio Analysis

              12.1.4.   Business Strategy & Recent Development

       12.2. Pfizer, Inc

              12.2.1.   Company overview

              12.2.2.   Financial performance

              12.2.3.   Route of Administration Portfolio Analysis

              12.2.4.   Business Strategy & Recent Development

       12.3. Johnson & Johnson Services, Inc

              12.3.1.   Company overview

              12.3.2.   Financial performance

              12.3.3.   Route of Administration Portfolio Analysis

              12.3.4.   Business Strategy & Recent Development

       12.4. Becton Dickinson

              12.4.1.   Company overview

              12.4.2.   Financial performance

              12.4.3.   Route of Administration Portfolio Analysis

              12.4.4.   Business Strategy & Recent Development

       12.5. F. Hoffmann-La Roche, Ltd

              12.5.1.   Company overview

              12.5.2.   Financial performance

              12.5.3.   Route of Administration Portfolio Analysis

              12.5.4.   Business Strategy & Recent Development

       12.6. Novartis AG

              12.6.1.   Company overview

              12.6.2.   Financial performance

              12.6.3.   Route of Administration Portfolio Analysis

              12.6.4.   Business Strategy & Recent Development

       12.7. 3M

              12.7.1.   Company overview

              12.7.2.   Financial performance

              12.7.3.   Route of Administration Portfolio Analysis

              12.7.4.   Business Strategy & Recent Development

       12.8. UniQure N.V.

              12.8.1.   Company overview

              12.8.2.   Financial performance

              12.8.3.   Route of Administration Portfolio Analysis

              12.8.4.   Business Strategy & Recent Development

       12.9. Shenzhen (SiBiono)

              12.9.1.   Company overview

              12.9.2.   Financial performance

              12.9.3.   Route of Administration Portfolio Analysis

              12.9.4.   Business Strategy & Recent Development

       12.10. Sulzer Ltd

              12.10.1. Company overview

              12.10.2. Financial performance

              12.10.3. Route of Administration Portfolio Analysis

              12.10.4. Business Strategy & Recent Development

       12.11. GeneTech Co. Ltd

              12.11.1. Company overview

              12.11.2. Financial performance

              12.11.3. Route of Administration Portfolio Analysis

              12.11.4. Business Strategy & Recent Development

       12.12. Antares Pharma, Inc

              12.12.1. Company overview

              12.12.2. Financial performance

              12.12.3. Route of Administration Portfolio Analysis

              12.12.4. Business Strategy & Recent Development

       12.13. GlaxoSmithKline plc

              12.13.1. Company overview

              12.13.2. Financial performance

              12.13.3. Route of Administration Portfolio Analysis

              12.13.4. Business Strategy & Recent Development

       12.14. AstraZeneca PLC

              12.14.1. Company overview

              12.14.2. Financial performance

              12.14.3. Route of Administration Portfolio Analysis

              12.14.4. Business Strategy & Recent Development

       12.15. Boehringer Ingelheim group

              12.15.1. Company overview

              12.15.2. Financial performance

              12.15.3. Route of Administration Portfolio Analysis

              12.15.4. Business Strategy & Recent Development

         12.16. Consort Medical plc (Recipharm Group)

              12.16.1. Company overview

              12.16.2. Financial performance

              12.16.3. Route of Administration Portfolio Analysis

              12.16.4. Business Strategy & Recent Development

       12.17. Insulet Corporation

              12.17.1. Company overview

              12.17.2. Financial performance

              12.17.3. Route of Administration Portfolio Analysis

              12.17.4. Business Strategy & Recent Development

       12.18. Medtronic Plc

              12.18.1. Company overview

              12.18.2. Financial performance

              12.18.3. Route of Administration Portfolio Analysis

              12.18.4. Business Strategy & Recent Development

    

 

List of Tables (86 Tables)

TABLE 1.  MARKET, By Route of Administration, 2021-2030 (USD Million)

TABLE 2.  MARKET FOR Oral, BY REGION, 2021-2030 (USD Million)

TABLE 3.  MARKET FOR Inhalation, BY REGION, 2021-2030 (USD Million)

TABLE 4.  MARKET FOR Transdermal, BY REGION, 2021-2030 (USD Million)

TABLE 5.  MARKET FOR Injectable, BY REGION, 2021-2030 (USD Million)

TABLE 6.  MARKET FOR Ocular, BY REGION, 2021-2030 (USD Million)

TABLE 7.  MARKET FOR Nasal, BY REGION, 2021-2030 (USD Million)

TABLE 8.  MARKET FOR Topical, BY REGION, 2021-2030 (USD Million)

TABLE 9.  MARKET FOR Others, BY REGION, 2021-2030 (USD Million)

TABLE 10. MARKET, By Application, 2021-2030 (USD Million)

TABLE 11. MARKET FOR Oncology, BY REGION, 2021-2030 (USD Million)

TABLE 12. MARKET FOR Infectious Diseases, BY REGION, 2021-2030 (USD Million)

TABLE 13. MARKET FOR Respiratory Diseases, BY REGION, 2021-2030 (USD Million)

TABLE 14. MARKET FOR Diabetes, BY REGION, 2021-2030 (USD Million)

TABLE 15. MARKET FOR Cardiovascular Diseases, BY REGION, 2021-2030 (USD Million)

TABLE 16. MARKET FOR Autoimmune Diseases, BY REGION, 2021-2030 (USD Million)

TABLE 17. MARKET FOR Central Nervous System Disorders, BY REGION, 2021-2030 (USD Million)

TABLE 18. MARKET FOR Others, BY REGION, 2021-2030 (USD Million)

TABLE 19. MARKET, BY END-USER, 2021-2030 (USD Million)

TABLE 20. MARKET FOR Hospitals, BY REGION, 2021-2030 (USD Million)

TABLE 21. MARKET FOR Diagnostic Centers, BY REGION, 2021-2030 (USD Million)

TABLE 22. MARKET FOR Ambulatory Surgery Centers/Clinics, BY REGION, 2021-2030 (USD Million)

TABLE 23. MARKET FOR Others, BY REGION, 2021-2030 (USD Million)

TABLE 24. MARKET, By Vehicles, 2021-2030 (USD Million)

TABLE 25. MARKET FOR Hydrogel, BY REGION, 2021-2030 (USD Million)

TABLE 26. MARKET FOR Micelle, BY REGION, 2021-2030 (USD Million)

TABLE 27. MARKET FOR Dendrimer, BY REGION, 2021-2030 (USD Million)

TABLE 28. MARKET FOR Nanoparticle, BY REGION, 2021-2030 (USD Million)

TABLE 29. MARKET FOR Liposome, BY REGION, 2021-2030 (USD Million)

TABLE 30. MARKET FOR Scaffold, BY REGION, 2021-2030 (USD Million)

TABLE 31. MARKET FOR Mesoporous Material, BY REGION, 2021-2030 (USD Million)

TABLE 32. MARKET FOR Niosomes, BY REGION, 2021-2030 (USD Million)

TABLE 33. MARKET, BY Home Care Settings, 2021-2030 (USD Million)

TABLE 34. MARKET, BY REGION, 2021-2030 (USD Million)

TABLE 35. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million)

TABLE 36. NORTH AMERICA MARKET, By Route of Administration, 2021-2030 (USD Million)

TABLE 37. NORTH AMERICA MARKET, By Application, 2021-2030 (USD Million)

TABLE 38. NORTH AMERICA MARKET, BY END-USER, 2021-2030 (USD Million)

TABLE 39. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million)

TABLE 40. EUROPE MARKET, By Route of Administration, 2021-2030 (USD Million)

TABLE 41. EUROPE MARKET, By Application, 2021-2030 (USD Million)

TABLE 42. EUROPE MARKET, BY END-USER, 2021-2030 (USD Million)

TABLE 43. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million)

TABLE 44. ASIA-PACIFIC MARKET, By Route of Administration, 2021-2030 (USD Million)

TABLE 45. ASIA-PACIFIC MARKET, By Application, 2021-2030 (USD Million)

TABLE 46. ASIA-PACIFIC MARKET, BY END-USER, 2021-2030 (USD Million)

TABLE 47. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million)

TABLE 48. LAMEA MARKET, By Route of Administration, 2021-2030 (USD Million)

TABLE 49. LAMEA MARKET, By Vehicles, 2021-2030 (USD Million)

TABLE 50. LAMEA MARKET, BY END-USER, 2021-2030 (USD Million)

TABLE 51. Bayer AG: COMPANY SNAPSHOT

TABLE 52. Bayer AG: OPERATING SEGMENTS

TABLE 53. Pfizer, Inc: COMPANY SNAPSHOT

TABLE 54. Pfizer, Inc: OPERATING SEGMENTS

TABLE 55. Johnson & Johnson Services, Inc: COMPANY SNAPSHOT

TABLE 56. Johnson & Johnson Services, Inc: OPERATING SEGMENTS

TABLE 57. Becton Dickinson: COMPANY SNAPSHOT

TABLE 58. Becton Dickinson: OPERATING SEGMENTS

TABLE 59. F. Hoffmann-La Roche, Ltd: COMPANY SNAPSHOT

TABLE 60. F. Hoffmann-La Roche, Ltd: OPERATING SEGMENTS

TABLE 61. Novartis AG: COMPANY SNAPSHOT

TABLE 62. Novartis AG: OPERATING SEGMENTS

TABLE 63. 3M: COMPANY SNAPSHOT

TABLE 64. 3M: OPERATING SEGMENTS

TABLE 65. UniQure N.V.: COMPANY SNAPSHOT

TABLE 66. UniQure N.V.: OPERATING SEGMENTS

TABLE 67. Shenzhen (SiBiono): COMPANY SNAPSHOT

TABLE 68. Shenzhen (SiBiono): OPERATING SEGMENTS

TABLE 69. Sulzer Ltd: COMPANY SNAPSHOT

TABLE 70. Sulzer Ltd: OPERATING SEGMENTS

TABLE 71. GeneTech Co. Ltd: COMPANY SNAPSHOT

TABLE 72. GeneTech Co. Ltd: OPERATING SEGMENTS

TABLE 73. Antares Pharma, Inc: COMPANY SNAPSHOT

TABLE 74. Antares Pharma, Inc: OPERATING SEGMENTS

TABLE 75. GlaxoSmithKline plc: COMPANY SNAPSHOT

TABLE 76. GlaxoSmithKline plc: OPERATING SEGMENTS

TABLE 77. AstraZeneca PLC: COMPANY SNAPSHOT

TABLE 78. AstraZeneca PLC: OPERATING SEGMENTS

TABLE 79. Boehringer Ingelheim group: COMPANY SNAPSHOT

TABLE 80. Boehringer Ingelheim group: OPERATING SEGMENTS

TABLE 81. Consort Medical plc (Recipharm Group): COMPANY SNAPSHOT

TABLE 82. Consort Medical plc (Recipharm Group): OPERATING SEGMENTS

TABLE 83. Insulet Corporation: COMPANY SNAPSHOT

TABLE 84. Insulet Corporation: OPERATING SEGMENTS

TABLE 85. Medtronic Plc: COMPANY SNAPSHOT

TABLE 86. Medtronic Plc: OPERATING SEGMENTS

 

List of Figures (24 Figures)

Figure 1 Market: Research Methodology Steps

Figure 2 Research Design

Figure 3 Breakdown of Primaries: Market

Figure 4 Research Methodology: Hypothesis Building

Figure 5 Market: Route of Administration-Based Estimation

Figure 6 Top 18 Companies with Highest No. Of Patent in Last 9 Years

Figure 7 No. Of Patents Granted Per Year, 2019–2021

Figure 8 Import Data for Drug Delivery Devices Market, By Country, 2016–2021 (USD Thousand)

Figure 9 Export Data for Drug Delivery Devices Market, By Country, 2016–2021 (USD Thousand)

Figure 10 Data Triangulation Methodology

Figure 11 Market, By Application, 2019 vs. 2025 (USD Million)

Figure 12 Market Share, By End-user, 2019 vs. 2025 (USD Million)

Figure 13 Market Share, By Route of Administration, 2019 vs. 2025 (USD Million)

Figure 14 Market Share, By Vehicles, 2019 vs. 2025 (USD Million)

Figure 15 Geographical Snapshot of the Market

Figure 16 Oral to Witness Higher CAGR in Market for Route of Administration Segment during Forecast Period.

Figure 17 Hospitals to Witness Higher CAGR in Market for End-user Segment during Forecast Period.

Figure 18 Cancer to Witness Higher CAGR in the Market for Application Segment during Forecast Period.

Figure 20 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019

Figure 21 Market: Drivers, Restraints, Opportunities, and Challenges

Figure 22 North America: Market Snapshot

Figure 23 Asia Pacific: Market Snapshot

Figure 24 Vendor Dive: Evaluation Overview